Detalhe da pesquisa
1.
Anti-IL23for nail psoriasis in real life: Results of efficacy and safety during a 52-week period.
Dermatol Ther
; 35(7): e15506, 2022 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-35411578
2.
Real-life effectiveness of Risankizumab according to body mass index: Results of an Italian multicentre retrospective study.
J Eur Acad Dermatol Venereol
; 2023 Apr 16.
Artigo
em Inglês
| MEDLINE | ID: mdl-37062048
3.
Risk of Skin Cancer in Patients with Psoriasis: Single-Center Retrospective Study Comparing Anti-TNFα and Phototherapy.
J Clin Med
; 13(9)2024 Apr 23.
Artigo
em Inglês
| MEDLINE | ID: mdl-38730981
4.
Pso-Reg: a web registry for psoriasis in real life.
Ital J Dermatol Venerol
; 158(3): 249-254, 2023 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-37278501
5.
Efficacy of risankizumab after intra-class switching between anti IL-23 antagonists: a multi-center, retrospective, real-life observation.
Ital J Dermatol Venerol
; 159(1): 64-65, 2024 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-37997317